Cidara Therapeutics (CDTX) Gets a Buy Rating from Cantor Fitzgerald


Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Cidara Therapeutics (NASDAQ: CDTX) today and set a price target of $15. The company’s shares opened today at $3.80, close to its 52-week low of $3.36.

Chen wrote:

“CDTX’s pipeline is focused on better ways to treat fungal and bacterial infections as well as influenza. We expect pipeline advancements to drive upwards earnings revisions to levels not yet reflected in the consensus. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $15.”

According to TipRanks.com, Chen is a 5-star analyst with an average return of 13.3% and a 39.6% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Amneal Pharmaceuticals Inc, and Aridis Pharmaceuticals Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cidara Therapeutics with a $14.50 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $8.55 and a one-year low of $3.36. Currently, Cidara Therapeutics has an average volume of 103.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Cidara Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of anti-infectives for the treatment of fungal infections. Its portfolio includes CD101 IV, CD101 Topical, and Cloudbreak.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts